Department of Genetic Engineering, Sungkyunkwan University, Suwon, Korea.
J Med Food. 2013 Jan;16(1):56-65. doi: 10.1089/jmf.2012.2374. Epub 2012 Dec 20.
HangAmDan-B (HAD-B) is a powdered mixture of eight ethnopharmacologically characterized folk medicines that is prescribed for solid masses and cancers in Korea. In view of the finding that macrophage-mediated inflammation is a pathophysiologically important phenomenon, we investigated whether HAD-B modulates inflammatory responses and explored the associated molecular mechanisms. The immunomodulatory activity of HAD-B in toll-like receptor-activated macrophages induced by lipopolysaccharide (LPS) was assessed by measuring nitric oxide (NO) and prostaglandin E(2) (PGE(2)) levels. To identify the specific transcription factors (such as nuclear factor [NF]-κB and signaling enzymes) targeted by HAD-B, biochemical approaches, including kinase assays and immunoblot analysis, were additionally employed. HAD-B suppressed the production of PGE(2) and NO in LPS-activated macrophages in a dose-dependent manner. Furthermore, the extract ameliorated HCl/EtOH-induced gastritis symptoms. Moreover, HAD-B significantly inhibited LPS-induced mRNA expression of inducible NO synthase and cyclooxygenase (COX)-2. Interestingly, marked inhibition of NF-κB and activating transcription factor was observed in the presence of HAD-B. Data from direct kinase assays and immunoblot analysis showed that HAD-B suppresses activation of the upstream signaling cascade involving spleen tyrosine kinase, Src, p38, c-Jun N-terminal kinase, and transforming growth factor β-activated kinase 1. Finally, kaempferol, but not quercetin or resveratrol was identified as a bioactive compound in HAD-B. Therefore, our results suggest that HAD-B possesses anti-inflammatory activity that contributes to its anticancer property.
羥胺丹-B(HAD-B)是一種粉末混合物,由八種具有民族藥學特徵的民間藥物組成,在韓國用於治療固體腫瘤和癌症。考慮到巨噬細胞介導的炎症是一種病理生理學上重要的現象,我們研究了 HAD-B 是否調節炎症反應,並探討了相關的分子機制。通過測量一氧化氮(NO)和前列腺素 E(2)(PGE(2))水平來評估 HAD-B 在脂多糖(LPS)激活的受體激活的巨噬細胞中的免疫調節活性。為了確定 HAD-B 靶向的特定轉錄因子(如核因子[NF]-κB 和信號酶),還使用了生化方法,包括激酶測定和免疫熒光分析。HAD-B 以劑量依賴的方式抑制 LPS 激活的巨噬細胞中 PGE(2)和 NO 的產生。此外,提取物改善了 HCl/EtOH 誘導的胃炎症狀。此外,HAD-B 顯著抑制 LPS 誘導的誘導型一氧化氮合酶和環氧化酶(COX)-2 的 mRNA 表達。有趣的是,在存在 HAD-B 的情況下觀察到 NF-κB 和激活轉錄因子的明顯抑制。直接激酶測定和免疫熒光分析的數據表明,HAD-B 抑制涉及脾酪氨酸激酶、Src、p38、c-Jun N-末端激酶和轉化生長因子β激活激酶 1 的上游信號級聯的激活。最後,確定羥胺丹-B 中的生物活性化合物為山奈酚,而非槲皮素或白藜蘆醇。因此,我們的結果表明 HAD-B 具有抗炎活性,這有助於其抗癌特性。